Medical/Pharmaceuticals

Metabolon Names Andrew Messick Chief Financial Officer

Seasoned life sciences finance leader brings deep expertise in operational excellence and M&A to support Metabolon's next stage of growth MORRISVILLE, N.C., Feb. 3, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life scienc...

2026-02-03 22:00 3705

NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer

NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nea...

2026-02-03 21:58 7306

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an inn...

2026-02-03 11:22 5538

Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai

TOKYO, Feb. 3, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projects for the development of drugs, diagnostics and vaccines for malaria, tuberculosis (TB), and neglected ...

2026-02-03 09:00 4112

ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization

ZEISS ARTEVO 750 and ZEISS ARTEVO 850 surgical microscopes provide ophthalmic surgeons in China with end-to-end workflow integration to improve efficiency, precision, and surgical safety. JENA, Germany and SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today that China...

2026-02-03 07:00 4463

NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer

NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Beg...

2026-02-02 22:39 9201

3Shape TRIOS 6 intraoral scanner wins the European Product Design Award (EPDA) 2025

COPENHAGEN, Denmark, Feb. 2, 2026 /PRNewswire/ -- 3Shape today announced that theTRIOS 6 intraoral scanner has been honored with the European Product Design Award (EPDA) 2025 in the category Industrial/Healthcare: Medical Products. The EPDA Award Statement: "TRIOS 6 combines cutting-edge functio...

2026-02-02 20:03 3693

DHL Health Logistics Singapore Expands Capabilities to Elevate Life Science & Healthcare Logistics

Strategic expansion positions Singapore as a strategic arm for healthcare logistics in the APAC region. * DHL Group invests €10 million in a new pharmaceutical hub in Singapore to enhance international logistics and healthcare logistics infrastructure across the Asia-Pacific region. * The ex...

2026-02-02 10:00 5535

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to implant FDA-approved novel defibrillation lead

The new technology is the world's smallest, catheter-delivered defibrillation lead AUSTIN, Texas, Feb. 2, 2026 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved no...

2026-02-02 09:08 3325

International Cancer Organizations Work Together to Meet the Needs of Women with Cancer in Vietnam

The National Comprehensive Cancer Network (NCCN) is collaborating with the Vietnam National Cancer Hospital (K Hospital) to adapt regional recommendations for treating breast and ovarian cancers. HANOI, Vietnam, Feb. 2, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an a...

2026-02-02 09:08 3223

Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes

HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ...

2026-01-30 19:54 5986

Philips Receives Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Excellence in Digital Pathology-Healthcare Informatics

Philips is recognized for its market-leading innovation and comprehensive digital pathology ecosystem, driving global transformation in diagnostics and healthcare informatics SAN ANTONIO, Jan. 30, 2026 /PRNewswire/ -- Frost & Sullivan

2026-01-30 02:00 5527

Zeus Launches PFX™ Platform and Introduces PFX Flex™ Sub-Lite-Wall™, Advancing the Future of Catheter Innovation

Polymer platform sets a new standard for catheter design with PTFE-like performance and expanded material flexibility ORANGEBURG, S.C., Jan. 29, 2026 /PRNewswire/ -- Zeus, a global leader in advanced polymer solutions, today announced the launch of PFX™, a breakthrough platform designed to advan...

2026-01-29 23:00 5670

Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao

BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackle...

2026-01-29 20:00 4275

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

-  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study -  The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial couple...

2026-01-29 19:00 5374

SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

* Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family * Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology * SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine...

2026-01-29 10:10 5454

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imaging i...

2026-01-29 07:43 4820

REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools

BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch ofStemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveragingOpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEd...

2026-01-28 22:00 4735

NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania'

NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content Advisory: Pre-Market Update + First Lady Melania Tr...

2026-01-28 21:55 7111

Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications

HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...

2026-01-28 19:39 4457
1234567 ... 394

Week's Top Stories